DIA
-
ACM Global Central Laboratory establishes Mumbai-based subsidiary
ACM Global Central Lab has advanced its hybrid central lab model in Mumbai with an operational facility dedicated to manage clinical trials testing in India and provide study support throughout Asia Pacific.
DIA | 15 May 2012
-
Gerresheimer acquires Neutral Glass
Gerresheimer AG is committed to growth in the emerging markets. It acquires a majority shareholding in the Indian company Neutral Glass & Allied Industries to help it achieve this aim.
DIA | 19 April 2012
-
Salix initiates Target 3 phase 3 study
Salix initiates Target 3 phase 3 study to assess repeat treatment efficacy and safety of Rifaximin 550MG TID in subjects with irritable bowel syndrome with diarrhea
DIA | 06 April 2012
-
Pharmaceutical companies from Japan, India and China are amongst Asia Pacific’s most innovative
Pharmaceutical companies from Japan, India and China were among Asia Pacific’s leading innovators last year according to one of two reports released by Thomson Reuters, which provide new insights into global patent and trademark trends throughout 2011.
DIA | 28 March 2012
-
Porex expands chromatography, SPE media offerings
Porex has enhanced its comprehensive line of chromatography and SPE Media solutions with versatile, high-performance porous materials and filters designed to endure the most challenging chromatography applications.
DIA | 31 January 2012
-
Agilent Technologies, Integrated Diagnostics enter into partnership
Agilent Technologies and Integrated Diagnostics announced a partnership to develop assays that detect major human diseases at very early stages to improve treatment outcomes.
DIA | 25 January 2012
-
Agilent Technologies, Integrated Diagnostics enter into partnership
Agilent Technologies and Integrated Diagnostics announced a partnership to develop assays that detect major human diseases at very early stages to improve treatment outcomes.
DIA | 16 January 2012
-
Phosphagenics licenses Diclofenac gel for Indian market
Phosphagenics has licensed TPM/diclofenac, its topical non-steroidal pain formulation, to Themis Medicare of Mumbai for the Indian market. This represents Phosphagenics’ first commercial deal in India and its first licensing agreement of its diclofenac product. Under the terms of the agreement, Themis Medicare is committed to pay Phosphagenics an undisclosed up-front fee and double-digit royalty payments on sales.
DIA | 06 January 2012
-
ViroMed receives approval for Phase II trial in the US for diabetic peripheral neuropathy
ViroMed announced that VM202-DPN, the company's proprietary DNA medicine for treatment of diabetic peripheral neuropathy, has received approval from the US FDA for a Phase II clinical trial.
DIA | 04 January 2012
-
AMRI appoints new President, India Operations
Subramanyam Maddala assumes leadership for AMRI’s Indian API manufacturing operations as well as responsibility for AMRI facility operations in Hyderabad and Aurangabad, India.
DIA | 14 October 2011
